What is NDC 47426-201?

47426-201 is the product NDC for Cinvanti (aprepitant), Aprepitant 130 mg/18mL injection, emulsion, listed with the FDA by Heron Therapeutics, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Heron Therapeutics, Inc., NDC labeler code 47426. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Cinvanti?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Cinvanti NDC 47426-201 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)47426-201Labeler and product segments. Claims need a package NDC.

Product NDC at billing width47426-0201Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
47426-201-01	47426020101	1 VIAL, GLASS in 1 CARTON (47426-201-01) / 18 mL in 1 VIAL, GLASSMarketed from Jan 3, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cinvanti
Generic name (nonproprietary): aprepitant
Active ingredients: Aprepitant — 130 mg/18mL
Dosage form: Injection, Emulsion
Route: Intravenous
Labeler: Heron Therapeutics, Inc.NDC labeler code 47426
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 209296
Marketing start: Jan 3, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2C9 Inducers (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Neurokinin 1 Antagonists (Mechanism)
Identifiers: Product ID 47426-201_94c147fd-c8bd-428c-911b-f1aba4ab8729SPL ID 94c147fd-c8bd-428c-911b-f1aba4ab8729SPL set ID 4c218d3a-a508-4abc-9ed8-a6e8e191d1b4RxCUI 1995150, 1995155UNII 1NF15YR6UY
Pharmacologic class: Substance P/Neurokinin-1 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N447426020101 followed by a unit qualifier and the quantity

Package 47426-0201-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 1, 2026.

Indications (excerpt from the label)

CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen. nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: acute and delayed na…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 47426-201

What is NDC 47426-201?: 47426-201 is the product NDC for Cinvanti (aprepitant), Aprepitant 130 mg/18mL injection, emulsion, listed with the FDA by Heron Therapeutics, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Cinvanti (Aprepitant).
What is the active ingredient?: Aprepitant.
Who is the labeler?: Heron Therapeutics, Inc., NDC labeler code 47426. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Cinvanti?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Cinvanti (Aprepitant) NDC 47426-201